# Quest Diagnostics Inc: overview

DGX · NYSE · CIK 1022079 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dgx.md) · [Financials](/companies/dgx/financials.md) · [Filings](/companies/dgx/filings.md) · [Insiders](/companies/dgx/insiders.md)

Latest reported revenue: [$3.10bn](/filings/0001022079-26-000108.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 23, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001022079-26-000108).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,621 d](/filings/0001022079-26-000015.md) | [2,652](/filings/0001022079-26-000043.md) | [2,761](/filings/0001022079-26-000070.md) | [2,816](/filings/0001022079-26-000108.md) | [2,806 d](/filings/0001022079-26-000015.md) | [2,895](/filings/0001022079-26-000043.md) | [3,043](/filings/0001022079-26-000070.md) | [3,097](/filings/0001022079-26-000108.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [13.8% d](/filings/0001022079-26-000015.md) | [13.0%](/filings/0001022079-26-000043.md) | [15.9%](/filings/0001022079-26-000070.md) | [13.7%](/filings/0001022079-26-000108.md) | [13.8% d](/filings/0001022079-26-000015.md) | [13.8%](/filings/0001022079-26-000043.md) | [15.1%](/filings/0001022079-26-000070.md) | [15.5%](/filings/0001022079-26-000108.md) |
| Net margin | % | [8.5% d](/filings/0001022079-26-000015.md) | [8.3%](/filings/0001022079-26-000043.md) | [10.2%](/filings/0001022079-26-000070.md) | [8.7%](/filings/0001022079-26-000108.md) | [8.7% d](/filings/0001022079-26-000015.md) | [8.7%](/filings/0001022079-26-000043.md) | [10.5%](/filings/0001022079-26-000070.md) | [10.1%](/filings/0001022079-26-000108.md) |
| Diluted EPS | $ per share | not reported | [1.94](/filings/0001022079-26-000043.md) | [2.47](/filings/0001022079-26-000070.md) | [2.16](/filings/0001022079-26-000108.md) | not reported | [2.24](/filings/0001022079-26-000043.md) | [2.84](/filings/0001022079-26-000070.md) | [2.78](/filings/0001022079-26-000108.md) |
| Free cash flow | $m | [341 d](/filings/0001022079-26-000015.md) | [197](/filings/0001022079-26-000043.md) | [436 d](/filings/0001022079-26-000070.md) | [419 d](/filings/0001022079-26-000108.md) | [307 d](/filings/0001022079-26-000015.md) | [164](/filings/0001022079-26-000043.md) | [459 d](/filings/0001022079-26-000070.md) | [445 d](/filings/0001022079-26-000108.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.8](/filings/0001022079-24-000041.md) | [9.9](/filings/0001022079-25-000044.md) | [9.3](/filings/0001022079-26-000015.md) | [9.9](/filings/0001022079-26-000015.md) | [11.0](/filings/0001022079-26-000015.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [22.1%](/filings/0001022079-24-000041.md) | [14.4%](/filings/0001022079-25-000044.md) | [13.6%](/filings/0001022079-26-000015.md) | [13.6%](/filings/0001022079-26-000015.md) | [14.1%](/filings/0001022079-26-000015.md) |
| Net margin | % | [18.5%](/filings/0001022079-24-000041.md) | [9.6%](/filings/0001022079-25-000044.md) | [9.2%](/filings/0001022079-26-000015.md) | [8.8%](/filings/0001022079-26-000015.md) | [9.0%](/filings/0001022079-26-000015.md) |
| Diluted EPS | $ per share | [15.55](/filings/0001022079-24-000041.md) | [7.97](/filings/0001022079-25-000044.md) | [7.49](/filings/0001022079-26-000015.md) | [7.69](/filings/0001022079-26-000015.md) | [8.75](/filings/0001022079-26-000015.md) |
| Free cash flow | $bn | [1.8](/filings/0001022079-24-000041.md) | [1.3](/filings/0001022079-25-000044.md) | [0.9](/filings/0001022079-26-000015.md) | [0.9](/filings/0001022079-26-000015.md) | [1.4](/filings/0001022079-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dgx/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-26 | [Pfeiffer Gary M](/insiders/1127304.md) | Director | Sale (S) | 1,203 | $243.00 | $292.3k | [Form 4](/filings/0001022079-26-000118.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.97bn | 9,275,411 |  | Added +103,119 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.53bn | 7,233,394 |  | Added +87,722 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.30bn | 6,131,045 |  | Added +49,645 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.17bn | 5,516,643 |  | Added +135,822 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $1.00bn | 4,744,473 |  | Added +732,241 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $748.6m | 3,520,438 |  | Reduced −326,018 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $662.6m | 3,137,873 |  | Added +51,565 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $521.5m | 2,460,497 |  | Reduced −19,223 |
| [EdgePoint Investment Group Inc.](/funds/1481669.md) | 2026-06-30 | $476.4m | 2,247,568 |  | Added +3,699 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $421.4m | 1,988,048 |  | Added +38,513 |

## Recent filings

[All 1,787 filings](/companies/dgx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:18 ET | [10-Q](/filings/0001022079-26-000108.md) | Quarterly report, period 2026-09-30 | 0001022079-26-000108 |
| 2026-10-22 | 06:53 ET | [8-K](/filings/0000947871-26-000941.md) | 8.01 Other events | 0000947871-26-000941 |
| 2026-10-22 | 06:49 ET | [8-K](/filings/0001022079-26-000097.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001022079-26-000097 |
| 2026-10-06 | 16:30 ET | [8-K](/filings/0000947871-26-000922.md) | 5.02 Departure or appointment of officers or directors | 0000947871-26-000922 |
| 2026-07-23 | 16:16 ET | [10-Q](/filings/0001022079-26-000070.md) | Quarterly report, period 2026-06-30 | 0001022079-26-000070 |
| 2026-07-23 | 06:46 ET | [8-K](/filings/0001022079-26-000067.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001022079-26-000067 |
| 2026-05-21 | 16:48 ET | [8-K](/filings/0001022079-26-000052.md) | 5.07 Shareholder vote results | 0001022079-26-000052 |
| 2026-05-08 | 16:15 ET | [8-K](/filings/0001104659-26-057938.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-057938 |
| 2026-05-01 | 16:15 ET | [8-K](/filings/0001104659-26-054141.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-054141 |
| 2026-04-22 | 16:12 ET | [10-Q](/filings/0001022079-26-000043.md) | Quarterly report, period 2026-03-31 | 0001022079-26-000043 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001022079-26-000015.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1022079
- Tickers: DGX
- Exchange: NYSE
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:31 ET. No prices; not investment advice.